Cell Therapy Deal Benchmarks (Beyond CAR-T)

Median Upfront

$103M

Range: $48M - $159M

Total Deal Value

$1.0B

Range: $558M - $1.5B

Royalty Rate

8.9% - 15.6%

Tiered up to 19.6%

Dev Milestones

$364M

Range: $204M - $524M

Model Your Deal

Market Analysis

Cell therapies beyond CAR-T -- including tumor-infiltrating lymphocytes (TIL), natural killer (NK) cells, and iPSC-derived therapies -- are generating increasing licensing activity. Phase 1 non-CAR-T cell therapy deals carry a median total deal value of $1.0B, with upfront payments from $48M to $159M. The promise of off-the-shelf allogeneic products and solid tumor efficacy drives pharma interest.

Development milestones dominate non-CAR-T cell therapy deals at $364M, reflecting the extensive clinical de-risking around manufacturing scalability, persistence, and GvHD management for allogeneic approaches. Commercial milestones of $228M reward the path to broad market adoption.

Royalty rates range from 8.9% to 15.6% at the base tier, escalating to 19.6% on peak sales. Off-the-shelf allogeneic platforms with solid tumor activity and reduced manufacturing complexity attract the highest valuations and most favorable deal structures.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for non-CAR-T cell therapies?

Phase 1 non-CAR-T cell therapy deals average $103M upfront with $1.0B total deal value. The early clinical stage results in milestone-heavy structures (90% milestones) to manage development risk.

How do TIL therapy deals compare to NK cell therapy deals?

TIL therapy deals benefit from clinical validation (FDA-approved Iovance product) and proven solid tumor efficacy, commanding higher upfronts. NK cell therapy deals, particularly iPSC-derived off-the-shelf approaches, attract higher total deal values due to scalable manufacturing and broader commercial potential but carry greater technical risk.

What drives premiums in allogeneic cell therapy deals?

Off-the-shelf manufacturing capability, reduced GvHD risk, persistence without lymphodepletion, solid tumor penetration data, and cost-of-goods advantages over autologous approaches are the primary premium drivers. iPSC-derived platforms with engineered functionality command the highest valuations.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Cell Therapy Deal Benchmarks (Beyond CAR-T)

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

CAR-T Deal Benchmarks

Gene Therapy Deals

Preclinical Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?